Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETAMINE HCL vs AMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Noncompetitive NMDA receptor antagonist; blocks glutamate binding, and modulates opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Induction and maintenance of general anesthesia,Procedural sedation and analgesia,Treatment-resistant depression (off-label),Acute pain management (off-label)
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV or 10-30 mcg/kg/min IV infusion; Subanesthetic: 0.1-0.5 mg/kg IV; Analgesic: IM 2-4 mg/kg; Intranasal 1-3 mg/kg. Frequency: single doses or continuous infusion per clinical need.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Terminal elimination half-life: 2–4 hours (alpha: 10–15 min, beta: 2.5–4 hr); prolonged in hepatic impairment and with repeated dosing (up to 12–24 hr for active metabolite norketamine).
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Hepatic; primarily via CYP3A4 and CYP2B6 to norketamine (active metabolite), then further metabolized by CYP2B6 and CYP2A6.
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Renal: 90% as metabolites (norketamine, dehydronorketamine, hydroxylated derivatives) and 4% unchanged; biliary/fecal: 3%; minor pulmonary exhalation.
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
47% bound primarily to albumin and alpha-1-acid glycoprotein.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
2–4 L/kg (large distribution due to high lipophilicity; deep tissue compartments).
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
IM: 93%; intranasal: 45–50%; oral: 17–20% (extensive first-pass metabolism).
IV: 100%; IM: >90%; Rectal: ~50% (variable).
No dose adjustment required for mild to moderate renal impairment (e GFR >=30 m L/min). Severe renal impairment (e GFR <30 m L/min): use with caution; no specific dosing guidelines; consider reduced doses and monitor for prolonged effects.
No adjustment required; pharmacokinetics unchanged in renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: consider 50% dose reduction. Child-Pugh C: avoid use or use extreme caution with significant dose reduction (e.g., 75% reduction) and monitor closely.
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV bolus or 5-20 mcg/kg/min IV infusion; IM: 2-5 mg/kg; Intranasal: 1-3 mg/kg. For procedural sedation: IV 0.5-1 mg/kg over 2-3 minutes; additional doses 0.25-0.5 mg/kg as needed. Weight-based dosing per kg.
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Elderly patients: start with lowest effective doses; typical induction dose 0.5-1 mg/kg IV; reduce maintenance infusion rates (e.g., 5-10 mcg/kg/min); monitor for increased sensitivity, cognitive impairment, and cardiovascular effects; consider dose reduction of 25-50% compared to younger adults.
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
None.
None
Emergence reactions (delirium, hallucinations) can occur; minimize with benzodiazepines.,Hemodynamic instability: increased heart rate and blood pressure (contraindicated in hypertension/aneurysm).,Potential for abuse and dependence; schedule III controlled substance.,Laryngospasm and respiratory depression, especially at higher doses.,Increased intracranial pressure and intraocular pressure.
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
Hypersensitivity to ketamine or any component,Conditions where significant blood pressure elevation is hazardous (e.g., aneurysms, uncontrolled hypertension),Severe coronary artery disease,Increased intracranial pressure or intraocular pressure,Pregnancy (only if benefit outweighs risk)
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
No known food interactions. Avoid alcohol and grapefruit juice due to potential CYP3A4 inhibition affecting metabolism.
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
Fetal risk cannot be ruled out; animal studies show adverse effects at maternal toxic doses. Human data limited; avoid in first trimester unless benefits outweigh risks. Potential for fetal neurotoxicity in third trimester; use only if clearly needed.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
M/P ratio unknown; ketamine enters breast milk in low amounts. Limited data; monitor infant for sedation. Weigh benefits against potential risks.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
No specific dose adjustments required for pregnancy; consider increased volume of distribution and clearance. Use lowest effective dose; titrate to desired effect with careful monitoring.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
Ketamine produces dissociative anesthesia with preserved airway reflexes and spontaneous respiration. Onset is rapid (30 seconds IV, 5 minutes IM). Emergence reactions (hallucinations, delirium) can be mitigated with benzodiazepines. Contraindicated in patients with elevated intracranial or intraocular pressure, hypertension, and severe coronary artery disease. Use with caution in psychiatric disorders. Subanesthetic doses are used for treatment-resistant depression and acute pain.
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
You may experience vivid dreams or confusion as the medication wears off.,Do not drive or operate machinery for at least 24 hours after receiving ketamine.,Avoid alcohol and other sedatives for 24 hours following treatment.,Inform your doctor if you have a history of high blood pressure, glaucoma, or psychiatric illness.,This medication may cause changes in perception or feeling of detachment during administration.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"The combination of ketamine and diamorphine can lead to additive central nervous system (CNS) depression and respiratory depression, increasing the risk of hypoxia, sedation, and respiratory arrest. Ketamine, an NMDA receptor antagonist, enhances opioid-induced analgesia but also potentiates the adverse effects of diamorphine, including hypotension and bradycardia. Patients may experience profound sedation, confusion, and cardiovascular instability, particularly at higher doses or in opioid-naive individuals."
"Ketamine, an NMDA receptor antagonist, may inhibit cytochrome P450 3A4 (CYP3A4) activity, which is responsible for the 25-hydroxylation of cholecalciferol (vitamin D3) to calcidiol (25-hydroxyvitamin D). This inhibition can reduce the conversion of cholecalciferol to its active form, potentially leading to decreased vitamin D levels and impaired calcium homeostasis. Clinically, this may increase the risk of vitamin D deficiency, contributing to bone demineralization, hypocalcemia, or secondary hyperparathyroidism in patients receiving long-term or high-dose ketamine therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETAMINE HCL vs AMIDATE, answered by our medical review team.
KETAMINE HCL is a General Anesthetic that works by Noncompetitive NMDA receptor antagonist; blocks glutamate binding, and modulates opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.. AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETAMINE HCL and AMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETAMINE HCL is: Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV or 10-30 mcg/kg/min IV infusion; Subanesthetic: 0.1-0.5 mg/kg IV; Analgesic: IM 2-4 mg/kg; Intranasal 1-3 mg/kg. Frequency: single doses or continuous infusion per clinical need.. The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETAMINE HCL and AMIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETAMINE HCL is classified as Category C. Fetal risk cannot be ruled out; animal studies show adverse effects at maternal toxic doses. Human data limited; avoid in first trimester unless benefits outweigh risks. Potential . AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.